IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA. RAHWAY, N.J., April 29, 2025--(BUSINESS WIRE)--Merck (NYS ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Last year, Keytruda generated ... approved a $30.2 million grant to Merck, contingent on the company’s decision to set up operations at the Chestnut Run Innovation & Science Park (CRISP ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

IF THERE’S one thing every American agrees on, it’s that politics has become vicious. There are plenty of explanations for ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 construction jobs expected on the job site. The laboratory component of the new site ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.